VITAL Info Session: Funding Opportunities & Programs
Join us for one of our info sessions to answer all your questions about Funding Opportunities and Programs made available through the VITAL Hub. This session is perfect for innovators, entrepreneurs, and biotech startups pioneering the future of innovative therapeutics solutions.
What to Expect:
Overview of the VITAL Award Programs: Learn more about our non-dilutive funding awards for:
DEV Awards ranging from $50K to $200K for the development, evaluation, and validation of therapeutics solutions in alignment with BARDA’s mission, and
PrEP Awards up to $4M for preclinical development and up to $7.5M for Phase 1 clinical trials.
Discover how our program supports biotech startups and university-based projects in the therapeutics space with comprehensive resources and expert mentorship to accelerate biotech innovation for infectious diseases and CBRN threats.
Q&A: Engage with the VITAL team and get answers to your specific questions, including the application process, differences between the funding awards, eligibility requirements, program benefits, and how to maximize your chances of securing a spot.
Who Should Attend:
Biotech entrepreneurs and startups
Innovators in the therapeutics sector
Researchers and academics looking to commercialize their innovations
We’re hosting multiple info sessions to fit your schedule. Below are all available dates:
Tuesday, Jul 15 at 9 AM EDT – You're viewing this session
Wednesday, Aug 13 at 11 AM EDT – Sign up here
Thursday, Sep 11 at 11 AM EDT – Sign up here
Monday, Sep 15 at 2 PM EDT – Sign up here
BARDA Accelerator Network (BAN)
Established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), the BARDA Accelerator Network (BAN) fosters the growth of health security innovation ecosystems globally and accelerates the development and commercialization of next-generation health security solutions.
The BAN, comprised of 5 hubs, will serve as a global network supporting early-stage companies from around the world developing next-generation medical countermeasures (MCMs). The Hubs are focused on Diagnostics/Medical Devices, Therapeutics/Vaccines, Digital Health Tools, Special Populations, and Enabling Technologies.
Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL)
VITAL is a BARDA Accelerator Network (BAN) Hub supporting the development and acceleration of next-generation therapeutic and vaccine platforms and technologies to promote health security. It is led by Start2 Group in partnership with Advise Connect Inspire (ACI) and BioInnovation Labs (BioLabs). VITAL provides a global innovation network to enable impactful collaborations between the U.S. and other health security communities and their innovation ecosystems around the world.